AngioDynamics stock
ANGONASDAQAngioDynamics, Inc., HealthcareISIN US03475V1017
39Score 39 out of 100, Weak
Price and trend
61 / 100
Price history
−5.3% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 4.4% below it.
Since June 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 45).
The price is 26% below its 52-week high. Largest decline in 20 years: 83% (November 2021 to March 2024).
Chart figures for advanced users
- SMA 50$13.49
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$12.55
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)45
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$9.70
- The lowest closing price of the last twelve months.
- Resistance$16.13
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- AngioDynamics, Inc. belongs to the Medical (Instruments & Supplies) industry (United States) and, with a market value of $504.23M, is number 42 of 44 companies in its industry on MEQIRI.
- In fiscal 2026 it reported revenue of $320.17M (up 9.5% year on year) and a loss of $36.74M.
- For fiscal 2027, analysts expect on average revenue of $337.93M (up 5.5%) and adjusted earnings per share of −$0.27.
Show more
- MEQIRI Score 39 out of 100 (Weak): rank 545 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $33.97M, financial debt $10.74M.Stability 60
Weaknesses
- Loss-makingLoss of $32.94M over the last 12 months.Fundamentals 20
- Volatile share priceVolatility 48% a year over the last 12 months.Stability 60
The score is held back by profitability and fundamentals.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 40 to 39.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 31 Aug 2026, revenue rose 8.2% on the twelve months before. Revenue has grown solidly since 2007, at about 6% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 55%, operating −12%, net −11%.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 6 Jan 2027in 54 days
- Last reported
- 8 Oct 2026EPS reported −$0.04 (expected −$0.11)above expectations
Analyst estimates
Analysts have raised their 2028 earnings estimate by 10.6% since 15 Oct 2026.
- Earnings per share
- −$0.27+2.5%
- Revenue
- $337.93M+0.1%
- Earnings per share
- −$0.10+10.6%
- Revenue
- $355.37M+0.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −18.8%Full-year guidance confirmed: gross margin 54% to 55%, adjusted EBITDA $13 million to $16 million, adjusted loss per share $0.29 to $0.24.
“For fiscal 2027, we expect gross margin to be in the range of 54% to 55%, We expect adjusted EBITDA to be in the range of $13 million to $16 million And finally, we expect adjusted loss per share in the range of $0.29 to $0.24.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 8 Oct 2026 (fiscal Q1 2027), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 2 insiders sold, $654,695 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at AngioDynamics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 39
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Instruments & Supplies)
The next larger and next smaller companies by market value
- LeMaitre VascularLMAT $1.78B70
- Kestra Medical TechnologiesKMTS $1.7B43
- STAAR SurgicalSTAA $1.34B44
- GerresheimerGXI.DE $1.21B48
- Safilo GroupSFL.MI $1.01B61
- Dynavox GroupDYVOX.ST $784.35M67
- EmbectaEMBC $364.32M63
- COLTENE HoldingCLTN.SW $347.49M61
ETFs that hold AngioDynamics
Held by 2 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.02% | 0.30% | €4.28B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.01% | 0.30% | €2.22B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 May 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Oct 2018)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.